专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2009012571A1 TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN 审中-公开
标题翻译：用于治疗与AMYLOID蛋白相关的疾病的组织KALLIKREIN
公开(公告)号：WO2009012571A1
公开(公告)日：2009-01-29
申请号：PCT/CA2008/001327
申请日：2008-07-18
申请人： GENESYS VENTURE INC. , WILLIAMS, Mark
发明人： WILLIAMS, Mark
IPC分类号： A61K38/48 , A61K31/00 , A61P25/28 , A61P9/00
CPC分类号： A61K36/16 , A61K31/14 , A61K31/407 , A61K31/685 , A61K38/00 , A61K38/4853 , A61K38/57 , A61K45/06 , A61K2300/00
摘要： ABSTRACT This invention relates to methods of treating Alzheimer's disease or symptoms thereof, and amnesic mild cognitive impairment or symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to uses of tissue kallikrein or a variant or active fragment thereof for the digesting or cleaving amyloid and the treatment of conditions benefiting from the digestion or cleavage of amyloid. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration.
摘要翻译：摘要本发明涉及治疗阿尔茨海默病或其症状的方法，以及遗忘性轻度认知障碍或其症状。本发明的方法包括施用治疗有效量的组织激肽释放酶，其变体或活性片段。本发明还涉及组织激肽释放酶或其变体或活性片段用于消化或切割淀粉样蛋白的用途，以及治疗有益于淀粉样蛋白的消化或切割的条件。本发明还涉及包含治疗有效量的组织激肽释放酶，其配制用于口服或鼻内给药的变体或活性片段的药物组合物。

12. 发明申请

WO2003094935A1 THE USE OF THE HUMAN URINARY KININOGENASE IN THE MANUFACTURE OF A MEDICINE FOR TREATING AND PREVENTING CEREBRAL EMBOLISM 审中-公开
公开(公告)号：WO2003094935A1
公开(公告)日：2003-11-20
申请号：PCT/CN2003/000345
申请日：2003-05-12
IPC分类号： A61K34/89
CPC分类号： A61K38/4853
摘要： The invention discloses the use of the human urinary kininogenase in the manufacture of a medicine for treating and preventing cerebral embolism. The invention provides a pharmaceutical dosage form comprising the human urinary kininogenase as active ingredient for the treatment and prevention of cerebral embolism.

13. 发明申请

WO9912576A3 METHODS AND COMPOSITIONS FOR TREATING CARDIAC AND RENAL DISORDERS WITH ATRIAL NATRIURETIC PEPTIDE AND TISSUE KALLIKREIN GENE THERAPY 审中-公开
标题翻译：用心房钠尿肽和组织激素治疗心脏和肾脏疾病的方法和组合物
公开(公告)号：WO9912576A3
公开(公告)日：1999-06-03
申请号：PCT/US9819267
申请日：1998-09-11
申请人： MUSC FOUND FOR RES DEV , CHAO LEE , CHAO JULIE
发明人： CHAO LEE , CHAO JULIE
IPC分类号： A61K38/22 , A61K38/48 , A61K48/00
CPC分类号： A61K38/4853 , A61K38/2242 , A61K48/00
摘要： The present invention provides a method for treating a nonhypertension-associated renal disorder in a subject having a nonhypertension associated renal disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating a nonhypertension-associated renal disorder. Also provided is a method of treating a nonhypertension-associated cardiac disorder in a subject having a nonhypertension-associated cardiac disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating the nonhypertension-associated cardiac disorder.
摘要翻译：本发明提供了用于治疗患有非高血压相关性肾病的受试者中与非高血压相关的肾病的方法，包括在该条件下向受试者施用编码组织激肽释放酶和/或编码心房利钠肽的核酸的核酸，编码组织激肽释放酶的核酸和/或编码心房钠尿肽的核酸在受试者的细胞中表达，从而治疗非高血压相关的肾病。还提供了治疗患有与非高血压相关的心脏疾病的受试者中的非高血压相关的心脏疾病的方法，包括在该条件下向受治疗者施用编码组织激肽释放酶和/或编码心房利钠肽的核酸的核酸，编码组织激肽释放酶的酸和/或编码心房钠尿肽的核酸在受试者的细胞中表达，从而治疗非高血压相关的心脏疾病。

14. 发明申请

WO99012576A2 METHODS AND COMPOSITIONS FOR TREATING CARDIAC AND RENAL DISORDERS WITH ATRIAL NATRIURETIC PEPTIDE AND TISSUE KALLIKREIN GENE THERAPY 审中-公开
标题翻译：用ATRIAL NATRIURETIC PEPTIDE和TISSUE KALLIKREIN基因治疗治疗心脏病和肾脏病的方法和组合物
公开(公告)号：WO99012576A2
公开(公告)日：1999-03-18
申请号：PCT/US1998/019267
申请日：1998-09-11
IPC分类号： A61K38/22 , A61K38/48 , A61K48/00
CPC分类号： A61K38/4853 , A61K38/2242 , A61K48/00
摘要： The present invention provides a method for treating a nonhypertension-associated renal disorder in a subject having a nonhypertension associated renal disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating a nonhypertension-associated renal disorder. Also provided is a method of treating a nonhypertension-associated cardiac disorder in a subject having a nonhypertension-associated cardiac disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating the nonhypertension-associated cardiac disorder.
摘要翻译：本发明提供了一种治疗患有非高血压相关肾病的受试者中的非高血压相关肾病的方法，包括向受试者施用编码组织激肽释放酶和/或编码心房钠尿肽的核酸的核酸，酸编码组织激肽释放酶和/或编码心房钠尿肽的核酸在受试者的细胞中表达，从而治疗非高血压相关性肾病。还提供了治疗具有非高血压相关心脏病的受试者中的非高血压相关心脏病症的方法，包括在条件下向受试者施用编码组织激肽释放酶和/或编码心房钠尿肽的核酸的核酸，酸编码组织激肽释放酶和/或编码心房利钠肽的核酸在受试者的细胞中表达，从而治疗非高血压相关心脏病。

15. 发明申请

WO2015100768A1 聚乙二醇化的组织激肽释放酶及其制备方法和应用审中-公开
公开(公告)号：WO2015100768A1
公开(公告)日：2015-07-09
申请号：PCT/CN2014/070344
申请日：2014-01-09
申请人：江苏众红生物工程创药研究院有限公司 , 常州京森生物医药研究所有限公司
发明人：马永 , 王俊 , 邱晶 , 吴鼎龙 , 徐春林 , 陈晨 , 王耀方
IPC分类号： A61K47/48 , C12N9/64 , A61P3/10
CPC分类号： A61K38/4853 , A61K47/48215 , A61K47/60 , C12N9/6445 , C12Y304/21035
摘要：聚乙二醇化的组织激肽释放酶及其制备方法和应用，涉及聚乙二醇修饰的蛋白类药物，所述组织激肽释放酶具有SEQ ID No.1或 SEQ ID No.2所示的序列，所述组织激肽释放酶可以是天然或重组的，其中聚乙二醇为分子量为20-40kDa的聚乙二醇，其中所述聚乙二醇在组织激肽释放酶的N 端伯氨基上偶联。本发明提供的聚乙二醇化的 KLK1，在具有半衰期明显延长、免疫原性显著降低、结构稳定均一的等优点的基础上，更大程度的提高了其生物活性，尤其在治疗脑卒中及糖尿病肾病方面更加显著。

16. 发明申请

WO2015054718A1 BONE FORMATION 审中-公开
标题翻译：骨形成
公开(公告)号：WO2015054718A1
公开(公告)日：2015-04-23
申请号：PCT/AU2014/000128
申请日：2014-02-14
申请人： THE UNIVERSITY OF SYDNEY
发明人： JACKSON, Christopher, John
IPC分类号： A61K38/36 , A61K38/18 , A61K31/662 , A61P19/08
CPC分类号： A61K31/675 , A61K38/1808 , A61K38/1875 , A61K38/37 , A61K38/4833 , A61K38/4853 , A61K2300/00
摘要： Use of APC for inducing or promoting bone formation.
摘要翻译：使用APC诱导或促进骨形成。

17. 发明申请

WO2013173923A1 FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS 审中-公开
标题翻译：人体组织KALLIKREIN-1用于全身输送和相关方法的制剂
公开(公告)号：WO2013173923A1
公开(公告)日：2013-11-28
申请号：PCT/CA2013/050395
申请日：2013-05-24
申请人： DIAMEDICA, INC.
发明人： CHARLES, Matthew
IPC分类号： A61K38/48 , A61P3/10
CPC分类号： A61K9/0019 , A61K38/4853
摘要： Provided are high concentration compositions of human tissue kallikrein-1 (hKLKl ) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety and/or convenience relative to other forms of administration. Also provided are recombinant human tissue KLKl (rhKLKl ) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof
摘要翻译：提供人组织激肽释放酶-1（hKLK1）的高浓度组合物和向有需要的受试者肠胃外给药的方法，其中通过例如静脉内或皮下给药吸收到循环中改善全身药代动力学，生物利用度，安全性和 /或相对于其他形式的管理的便利。还提供了可以容易地浓缩到高蛋白质浓度的重组人组织KLK1（rhKLK1）多肽，并且其基本上纯的组合物

18. 发明申请

WO2010056765A3 ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS 审中-公开
标题翻译：用于因子XA抑制剂的抗体及其与血液凝结剂组合使用的方法
公开(公告)号：WO2010056765A3
公开(公告)日：2010-08-05
申请号：PCT/US2009064060
申请日：2009-11-11
申请人： PORTOLA PHARM INC , LU GENMIN , SINHA UMA
发明人： LU GENMIN , SINHA UMA
IPC分类号： A61K38/48 , A61K35/14 , A61P7/04
CPC分类号： A61K38/36 , A61K35/16 , A61K38/16 , A61K38/37 , A61K38/482 , A61K38/4826 , A61K38/4833 , A61K38/4846 , A61K38/4853 , A61K45/06 , A61K2300/00
摘要： The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.
摘要翻译：本发明涉及靶向凝血因子Xa的抗凝剂的解毒剂，其中解毒剂与凝血剂或其他肝素解毒剂组合使用以预防或减少受试者的出血。本文所述的解毒剂具有降低的或不具有内在凝固剂活性。本文公开了停止或预防正在或将要用Xa因子抑制剂进行抗凝血剂治疗的患者出血的方法。

19. 发明申请

WO2010020423A3 METHODS FOR TREATING BLEEDING DISORDERS 审中-公开
标题翻译：治疗出血性疾病的方法
公开(公告)号：WO2010020423A3
公开(公告)日：2010-05-27
申请号：PCT/EP2009006082
申请日：2009-08-21
申请人： BAXTER HEALTHCARE SA , BAXTER INT , DOCKAL MICHAEL , SCHEIFLINGER FRIEDRICH , TURECEK PETER
发明人： DOCKAL MICHAEL , SCHEIFLINGER FRIEDRICH , TURECEK PETER
IPC分类号： A61K31/737 , A61K31/727 , A61P7/04
CPC分类号： A61K31/737 , A61K31/727 , A61K38/36 , A61K38/366 , A61K38/37 , A61K38/4846 , A61K38/4853 , A61K45/06 , G01N33/86 , A61K2300/00
摘要： A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor Xl; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor Xl-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.
摘要翻译：在需要增强血液凝固的受试者中增强因子XI依赖性血液凝固的方法，包括向受试者施用治疗有效量的包含非抗凝血剂硫酸化多糖（NASP）的组合物。一种在需要增强血液凝固的受试者中增强因子XI依赖性血液凝固的方法，包括：（i）选择对于因子XI不缺乏的受试者; 和（ii）将治疗有效量的包含非抗凝血剂硫酸化多糖（NASP）的组合物给予所述受试者，其中所述NASP以因子XI依赖性方式增强凝血。一种鉴定能够根据FXI增强血液凝固的非抗凝血硫酸化多糖（NASP）的方法，所述方法包括：a）将包含活化能力FXI的血液或血浆样品与包含硫酸化多糖的组合物混合并测量血液或血浆样品的凝血或凝血酶生成参数; b）将缺乏活化能力的FXI的相应血液或血浆样品与包含硫酸化多糖的组合物组合并测量血液或血浆样品的凝固或凝血酶生成参数; 和c）将在步骤（a）和（b）中确定的血液或血浆样品的凝血或凝血酶生成参数彼此比较，其中血样的凝固时间减少或峰值凝血酶增加或降低在包含活化能力FXI的血浆样品的峰值时间与血液样品或峰值凝血酶的凝固时间相比较或缺乏活化能力的血浆样品的峰值时间FXI表明NASP能够依赖于 FXI。

20. 发明申请

WO2010020423A2 METHODS FOR TREATING BLEEDING DISORDERS 审中-公开
标题翻译：治疗瘫痪病的方法
公开(公告)号：WO2010020423A2
公开(公告)日：2010-02-25
申请号：PCT/EP2009/006082
申请日：2009-08-21
申请人： BAXTER HEALTHCARE S.A. , BAXTER INTERNATIONAL INC. , DOCKAL, Michael , SCHEIFLINGER, Friedrich , TURECEK, Peter
发明人： DOCKAL, Michael , SCHEIFLINGER, Friedrich , TURECEK, Peter
IPC分类号： A61K31/737 , A61K31/727 , A61P7/04
CPC分类号： A61K31/737 , A61K31/727 , A61K38/36 , A61K38/366 , A61K38/37 , A61K38/4846 , A61K38/4853 , A61K45/06 , G01N33/86 , A61K2300/00
摘要： A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor Xl; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor Xl-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.
摘要翻译：一种需要增强血液凝固的受试者中因子X1依赖性血液凝固增强的方法，其包括给受试者施用治疗有效量的包含非抗凝血硫酸多糖（NASP）的组合物。一种需要增强血液凝固的受试者中因子X1依赖性血液凝固增强的方法，包括：（i）选择对于因子X1不是不足的受试者; 和（ii）向所述受试者施用治疗有效量的包含非抗凝血硫酸多糖（NASP）的组合物，其中所述NASP以因子X1依赖性方式增强血液凝固。一种鉴定能够根据FXI增强血液凝固的非抗凝血硫酸多糖（NASP）的方法，所述方法包括：a）将包含活化能力的FXI的血液或血浆样品与包含硫酸化多糖的组合物和测量血液或血浆样品的凝血酶或凝血酶产生参数; b）将活化受体FXI中缺乏的相应血液或血浆样品与包含硫酸化多糖的组合物结合并测量血液或血浆样品的凝血酶或凝血酶产生参数; 和c）比较步骤（a）和（b）中确定的血液或血浆样品的凝血酶或凝血酶产生参数，其中血液样品的凝血时间的降低或峰值凝血酶的增加或减少在包含活化能力的FXI的血浆样品的峰值时间与血液样品的凝血时间或峰值凝血酶相比或缺乏活化能力的FXI的血浆样品的峰值时间指示NASP，其能够依赖于 FXI。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式